Acute kidney injury (AKI) is defined as functional or structural abnormalities of the kidneys that cause sudden impairment of fluid homeostasis, resulting in retention of metabolic products over a period of hours to days. Diagnosis of AKI is challenging. Sometimes the symptoms are not evident, and they can be fatal by the time they are noticeable. The disease is increasingly common and potentially a catastrophic complication in hospitalized patients. This content examines the management of AKI from the perspective of nephrologists and critical care physicians. It provides a detailed and expanded analysis on the causes of AKI, the utility of current diagnosis methods, AKI staging criteria, and the treatment of AKI (such as fluid management, continuous veno-venous hemofiltration, intermittent hemodialysis, N-acetylcysteine, prednisone, and sodium bicarbonate). In addition, it discusses how nephrologists and critical care physicians perceive future treatment of AKI.
- What are the common underlying causes of AKI?
- What are the comorbidities and risk factors associated with AKI?
- What percentage of patients present with AKI versus develop it in the hospital?
- What are the roles and utility of biomarkers in diagnosing AKI and assessing the efficacy of treatment?
- What are the main challenges faced in the management of AKI?
- How frequently do physicians use RIFLE, AKIN, and KDIGO guidelines for AKI?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.
Survey of 64 nephrologists and 36 critical care physicians in the United States.
KEY TREATMENTS COVERED
Intermittent hemodialysis, continuous veno-venous hemofiltration, fluid management, sodium bicarbonate, N-acetylcysteine, prednisone
- Acute Kidney Injury - Current Treatment - Detailed, Expanded Analysis (US)
- Current Treatment: Physician Insights Acute Kidney Injury US (Full Report)
Author(s): Rameshwar Prajapati, Ph.D., M.S. (Pharm.)
Rameshwar Prajapati, Ph.D., M.S. (Pharm.), is a business insights analyst in Decision Resources Group’s cardiovascular, metabolic, renal, and hematologic disorders team, focusing primarily on obesity. In this role, his main function is to perform primary and secondary research related to obesity and its treatment, as well as providing insights and assessments for the major pharmaceutical markets regarding weight loss medications.
Rameshwar holds a bachelor’s degree in pharmacy from Dr. H.S. Gour University, Sagar, India. He obtained his master’s and doctorate degree in pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, S.A.S Nagar, India. Rameshwar also received a German Academic Exchange Service (DAAD) fellowship to conduct his research on P-glycoprotein at the University of Bonn, Germany.